Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board

| Source: Bavarian Nordic A/S
KVISTGAARD, Denmark, April 24, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today, that following the ordinary general meeting, the board
has elected Gerard van Odijk, M.D. as new chairman of the board of Bavarian
Nordic. He succeeds Asger Aamund who has served as chairman since 1994.
Furthermore Anders Gersel Pedersen, M.D. has been elected deputy chairman of the

Dr. van Odijk has served as board member in Bavarian Nordic since 2008. He is an
independent advisor for the pharmaceutical industry in which he has long-time
experience from various executive positions. He retired as president and CEO of
Teva Pharmaceuticals Europe B.V. in 2012 and has previously held various senior
positions in GlaxoSmithKline (GSK).

Dr. van Odijk is also chairman of the board of Merus Biopharmaceuticals B.V. and
member of the board of UDG Healthcare plc. He is a Dutch national, born in 1957.

Anders Gersel Pedersen, M.D. and deputy chairman has served on the board since
2010. Dr. Pedersen is executive vice president of research and development at H.
Lundbeck A/S. He is deputy chairman of the board of Genmab A/S and a member of
the board of directors of ALK-Abelló A/S. Dr. Pedersen is a Danish national,
born in 1951.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "After having served
on the board for more than five years, we are happy to welcome Gerard as new
chairman of the board. His inside knowledge from our company combined with his
extensive executive background within publicly traded companies in the
international pharmaceutical industry will contribute to our continued progress
in the coming years."

Anders Hedegaard, President & CEO.

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone
+45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.